Mp53-08 Metformin Use Is Associated With Improved Survival in Veterans With Advanced Prostate Cancer on Androgen Deprivation Therapy
Year: 2017
Type: article
Study design: Observational Study
Abstract: non-castration-resistant prostate cancer affects the further therapeutic effect of docetaxel when patients become castration resistant.Herein, our aim was to investigate the prognostic value of response duration of ADT in castration-resistant prostate cancer (CRPC) treated with docetaxel chemotherapy.METHODS: We retrospectively reviewed the medical records of 201 patients who received ADT therapy before docetaxel treatment.Docetaxel at a dose of 75 mg/m 2 was administered every 3 or 4 weeks.We defined the effective period of first ADT based upon prostate cancer clinical trials working group 3 (PCWG-3) criteria.Patient clinico-pathological data were collected to assess the prognostic factors for cancerspecific survival (CSS).RESULTS: Among the 201 patients, median age was 73 years and the median follow-up period was 45.5 months.Bone metastases were found in 134 (66.7%) patients, and 85 (42.3%) patients had an EOD grade of 2 or higher.Visceral metastases were found in 47 patients (23.4%).Median CSS and progression-free survival were 21.5 months and 13.5 months, respectively.The median response duration of ADT was 29.2 months.Overall, 121 (60.2%) patients achieved PSA nadir <0.2 ng/ml during first ADT.According to the Kaplan-Meier method, the 2-year CSS rate for first ADT !16 months was 62.9%, whereas the counterpart was 32.1% (p<0.001).Furthermore, the 2-year survival rate for nadir PSA <0.2 ng/ml was 65.4%, whereas the counterpart was 40.2% (p¼0.002).Multivariate analysis indicated that first ADT response <16 months, pretreatment PSA level !20 ng/ml, visceral metastasis, and ALP !284 were independent prognostic factors for CSS (HR¼2.28,HR¼1.69,HR¼2.65, and HR¼1.98, respectively).However, the degree of nadir PSA level during ADT did not have a significant association with CSS.CONCLUSIONS: Our results clearly suggested that the effective duration of first ADT was a significant biomarker for predicting the treatment response for CRPC treated with first-line docetaxel.
Source: The Journal of Urology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2604600785